CME Group has said it is positioned to benefit from growth in exchange traded alternatives to over-the-counter (OTC) derivatives, as tailwinds emerge in the key US market.
Speaking to Global Investor Paul Woolman, the exchange's global head of equity index products, said the group plans to capitalise on regulatory changes like the Basel Uncleared Margin Rules (UMR), which had its widest implementation take effect in September last year. That has led to increased demand for products like its version of the total return future, called adjusted interest rate total return futures (TRFs). When I look at the US market, it has historically been less developed than Euro
Continue reading with a subscription to the SRP market intelligence platform.
Request a demoAlready a subscriber? Login